Long-Term Follow-up of Subjects Who Were Treated With ST-920

May 21, 2025 updated by: Sangamo Therapeutics

Long-Term Follow-up of Fabry Disease Subjects Who Were Treated With ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy

Long-term follow-up of subjects who received ST-920 in a previous trial (ST-920-201) and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 5 years following ST-920 infusion.

Study Overview

Status

Enrolling by invitation

Conditions

Intervention / Treatment

Detailed Description

Non-interventional, multi-center, long-term follow-up (LTFU) study of subjects dosed with ST-920 in the clinical study ST-920-201. All subjects dosed in the study who completed at least 52 weeks post-infusion follow-up in their primary protocol will be offered to participate. Subjects who enroll will be monitored for a total of up to 5 years following ST-920 infusion.

Study Type

Observational

Enrollment (Estimated)

48

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Australia
    • Victoria
      • Parkville, Victoria, Australia, 3050
        • The Royal Melbourne Hospital
  • Canada
    • Alberta
      • Calgary, Alberta, Canada, T2E 7Z4
        • M.A.G.I.C. Clinic Ltd.
  • Germany
      • Würzburg, Germany
        • University Hospital of Würzburg
  • United Kingdom
      • Cambridge, United Kingdom, CB2 0QQ
        • Addenbrooke's Hospital
      • London, United Kingdom
        • Royal Free Hospital
  • United States
    • California
      • Irvine, California, United States, 92697
        • University of California, Irvine
    • Florida
      • Tampa, Florida, United States, 33620
        • University of South Florida
    • Georgia
      • Atlanta, Georgia, United States, 30322
        • Emory University School of Medicine
    • Iowa
      • Iowa City, Iowa, United States, 52242
        • University of Iowa Hospital and Clinics
    • Minnesota
      • Minneapolis, Minnesota, United States, 55455
        • University of Minnesota Medical Center
    • New York
      • New York, New York, United States, 10029
        • Mt. Sinai Hospital
    • Ohio
      • Cincinnati, Ohio, United States, 45229
        • Cincinnati Children's Hospital Medical Center
    • Virginia
      • Fairfax, Virginia, United States, 22030
        • Lysosomal & Rare Disorders Research & Treatment Center (LDRTC)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

All subjects who have received ST-920 in separate parent trial and who have consented to participate in this Long Term Follow-up study.

Description

Inclusion Criteria:

  • Subjects who received ST-920 therapy in a separate parent trial
  • Subjects who have consented to participate in this LTFU study.

Exclusion Criteria:

-This study has no exclusion criteria

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Subjects who received ST-920
Subjects who received ST-920 in a separate parent trial
Biological: ST-920
No study drug is administered in this study. Subjects who received ST-920 in a separate parent trial will be evaluated in this trial for long-term safety.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To evaluate long-term safety of ST-920
Time Frame: 4 years
To evaluate long-term safety of ST-920 by assessment of incidence and severity of adverse events (AEs)
4 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sangamo Therapeutics

Investigators

  • Study Director: Medical Monitor, Sangamo Therapeutics, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 16, 2021

Primary Completion (Estimated)

March 1, 2029

Study Completion (Estimated)

March 1, 2039

Study Registration Dates

First Submitted

August 20, 2021

First Submitted That Met QC Criteria

September 1, 2021

First Posted (Actual)

September 10, 2021

Study Record Updates

Last Update Posted (Actual)

May 25, 2025

Last Update Submitted That Met QC Criteria

May 21, 2025

Last Verified

May 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ST-920-LT01

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Fabry Disease

Clinical Trials on ST-920

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe